<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Resist Infect Control</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Resist Infect Control</journal-id><journal-title-group><journal-title>Antimicrobial Resistance and Infection Control</journal-title></journal-title-group><issn pub-type="epub">2047-2994</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001254</article-id><article-id pub-id-type="pmc">PMC11863462</article-id>
<article-id pub-id-type="publisher-id">1527</article-id><article-id pub-id-type="doi">10.1186/s13756-025-01527-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Risk factors for detection of <italic>Pseudomonas aeruginosa</italic> in clinical samples upon hospital admission</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reyle</surname><given-names>Romeo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwab</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saydan</surname><given-names>Selin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Behnke</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Leistner</surname><given-names>Rasmus</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gastmeier</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Geffers</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2728-9399</contrib-id><name><surname>Kramer</surname><given-names>Tobias Siegfried</given-names></name><address><email>Tobias.Kramer@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Institute of Hygiene and Environmental Medicine, </institution><institution>Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Hindenburgdamm 27, 12203 Berlin, Germany </aff><aff id="Aff2"><label>2</label>National Reference Center for the Surveillance of Nosocomial Infections, 12203 Berlin, Germany </aff><aff id="Aff3"><label>3</label>LADR der Laborverbund Dr. Kramer &#x00026; Kollegen, 21502 Geesthacht, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Department of Gastroenterology, Infectious Diseases and Rheumatology, </institution><institution>Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Hindenburgdamm 30, 12203 Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>14</volume><elocation-id>17</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background/introduction</title><p id="Par1">Antipseudomonal antibiotics are frequently used in patients admitted to hospitals. Many of these substances are classified as a reserve or watch status by the WHO. Inappropriate risk assessment of invasive detection of <italic>P. aeruginosa</italic> (PAE) can be a reason for overuse of antipseudomonal antibiotics. Therefore it is important to define relevant and specific risk factors for invasive PAE detection.</p></sec><sec><title>Objective</title><p id="Par2">The objective of this study was to identify risk factors for invasive detection of PAE in patients upon hospital admission.</p></sec><sec><title>Methods</title><p id="Par3">All patients 18 years of age and older with a detection of PAE and/or Enterobacterales in clinical samples taken within 48&#x000a0;h of admission to one of the hospitals of Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin between 2015 and 2020 were included into this retrospective cohort study.</p></sec><sec><title>Results</title><p id="Par4">Overall, we included a total of 27,710 patients. In 3,764 (13.6%) patients PAE was detected in clinical samples taken within 48&#x000a0;h after admission. The most frequently detected Enterobacterales was <italic>E. coli</italic> in 14.142 (51%) patients followed by <italic>Klebsiella spp</italic>. in 4.432 (16%) patients. Multivariable regression analysis identified that prior colonisation with a multi drug resistant PAE or detection of a PAE in clinical samples during a previous hospitalisation increased the risk for invasive detection of PAE (OR 39.41; 95% CI 28.54&#x02013;54.39) and OR 7.87 (95% CI 6.60&#x02013;9.38) respectively. Admission to a specialised ward for patients with cystic fibrosis was associated with an increased risk (OR 26.99; 95% CI 20.48&#x02013;35.54). Presence of chronic pulmonary disease (OR 2.05; 95% CI 1.85&#x02013;2.26), hemiplegia (OR 2.16; 95% CI 1.90&#x02013;2.45) and male gender (OR 1.60; 95% CI 1.46&#x02013;1.75) were associated with a modest increase in risk for presence of PAE.</p></sec><sec><title>Conclusion</title><p id="Par5">Patients with a prior detection of <italic>P. aeruginosa</italic> or admission to a cystic fibrosis ward had the highest risk for invasive detection of <italic>P. aeruginosa.</italic> Adherence to specific risk scores based on local risk factors could help to optimize prescription of anti-pseudomonal antibiotics that categorized as reserve and watch.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Empirical antimicrobial therapy</kwd><kwd>Antimicrobial stewardship</kwd><kwd>Risk factor</kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>Antipseudomonal coverage</kwd><kwd>Watch list</kwd><kwd>Reserve list</kwd></kwd-group><funding-group><award-group><funding-source><institution>Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin (3093)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">The increase of antimicrobial resistance is an essential threat to human healthcare [<xref ref-type="bibr" rid="CR1">1</xref>]. Cassini et al. estimate that more than 33,110 deaths in Europe are caused by multidrug resistant pathogens [<xref ref-type="bibr" rid="CR2">2</xref>]. In Germany an increase of healthcare associated infection with multidrug resistant gram negative pathogens is observable [<xref ref-type="bibr" rid="CR3">3</xref>]. Antimicrobial Stewardship is one of the most important strategies against antimicrobial resistance [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Improved and rational use of antimicrobial substances could lower resistance rates [<xref ref-type="bibr" rid="CR6">6</xref>]. In Europe most antibiotics in hospitals are prescribed for community acquired infections with a third of prescriptions potentially covering <italic>Pseudomonas aeruginosa</italic> (PAE) [<xref ref-type="bibr" rid="CR7">7</xref>]. In German hospitals antibiotics with anti-pseudomonal coverage are also frequently used in patients with community and healthcare associated infections [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Substances such as Piperacillin-Tazobactam, Meropenem and Ciprofloxacin account for a quarter of all prescriptions. In its aWaRe classification the WHO has categorised most of antipseudomonal antibiotics to the watch or reserve group [<xref ref-type="bibr" rid="CR10">10</xref>]. An update of EUCAST criteria in 2020 regarding the meaning of the category &#x0201e; Susceptible, increased Exposure&#x0201c; might have further increased the use of these substances [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par7">De-escalation of antimicrobial therapies is an essential and recommended tool of antimicrobial stewardship [<xref ref-type="bibr" rid="CR12">12</xref>]. It is safe and effective even in cases with an increased risk for PAE lower respiratory tract infection [<xref ref-type="bibr" rid="CR13">13</xref>] and suspected sepsis [<xref ref-type="bibr" rid="CR14">14</xref>]. However, de-escalation is only performed in a fraction of antibiotic prescriptions [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par8">Despite the urgent need to improve prescription quality for antipseudomonal antibiotics, only little is known about the reasons for prescriptions of these broad-spectrum antibiotics.</p><p id="Par9">In guidelines risk factors for PAE as a potential cause of lower respiratory tract infections are frequently mentioned, but infrequently reported and or weighted [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. For other types of infections, only few studies exist for specific patient populations [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par10">Therefore, we aim to identify risk factors for detection of PAE in clinical samples acquired within 48&#x000a0;h after hospital admission that are easy asses. In order to potentially improve selection of antipseudomonal antibiotics in this setting.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par11">We identified all patients 18 years and older that were admitted to one of the three hospitals of Charit&#x000e9; Universit&#x000e4;tsmedizin Berlinwhich has all together account for about 3000 beds. Prior to the start of the study, we obtained a positive vote from the Charit&#x000e9; Ethics Board (internal processing key EA1/264/21). This investigation was then performed as a retrospective cohort study. Cases were identifiedfrom the Institutions own database. We included all cases in patients 18 years of age or older with a finding of PAE and/or Enterobacterales in clinical samples obtained within 48&#x000a0;h of admission. Samples were stratified according to their collection site. In case of multiple samples from a single patient, the most invasive location was chosen.</p><p id="Par12">Cases were defined as patients with the first invasive detection of PAE in a sample taken within 48&#x000a0;h of admission during the study period. Patients that had both invasive PAE and Enterobacterales were accounted to the PAE group. Colonization with PAE was defined as any detection of PAE in the patient during the 12 months prior to admission. Mortality was assessed based on discharge alive or in-hospital death.</p><p id="Par13">For all of the patients enrolled, the following clinical and demographic characteristics were collected: age, sex, in-hospital death, length of hospital stay (LOS); type of initial ward admitted to, specialty of ward admitted to, stay on an intensive care unit (days)previous detection of any PAE prior to the admission and known colonisation or previous infection with multidrug resistant gram negative rod bacteria. Length of stay in total were defined as length of stay until death or discharge. The Charlson comorbidity index (CCI) was obtained based on the patients&#x02019; diagnosed comorbidities while using the method of Charlson et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and the adaptation for the ICD-10 by Thygesen et al. [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Microbiological methods</title><p id="Par14">Microbiological sampling was performed at the treating physician&#x02019;s discretion. The samples were at least cultured for forty-eight hours. MALDI TOF MS<sup>&#x000ae;</sup> and Vitek 2<sup>&#x000ae;</sup> automated system (Biomerieux, Marcy l&#x02019;etoile, France) were used for identification and susceptibility testing of bacterial strains. Interpretation of susceptibility happened according to the updated EUCAST definitions at each point in time. Gram negative rods with non-intrinsic resistance against 3rd generation cephalosporins, fluorchinolone and/or carbapenems were defined as MDRGN according to the national recommendations.</p></sec><sec id="Sec5"><title>Statistical methods</title><p id="Par15">In the descriptive analysis, the median and the interquartile range (IQR) (25% percentile, 75% percentile) were calculated for continuous parameters and the number and percentage were calculated for binary parameters. Descriptive analysis was performed for the total cohort of patients with positive clinical sample caused by gram-negative pathogens within 48&#x000a0;h after hospital admission and stratified by the presence of PAE or not. Differences were tested using Wilcoxon rank-sum test for continuous variables or Chi-square test for binary variables respectively.</p><p id="Par16">The following patient-based parameters were considered in the analysis: age, gender (male/female) and comorbidities. In addition, the following non-patient-based parameters were used in the analysis:</p><p id="Par17">
<list list-type="bullet"><list-item><p id="Par18">the type of unit, where the clinical sample was taken (ICU, IMC, regular ward; specialization).</p></list-item><list-item><p id="Par19">the type of clinical sample (subgroup).</p></list-item><list-item><p id="Par20">the year and the season, when the clinical sample was taken and.</p></list-item><list-item><p id="Par21">detection of <italic>Pseudomonas aeruginosa</italic> in clinical samples prior to the admission.</p></list-item><list-item><p id="Par22">colonization with multidrug resistant gram negative bacteria (MDRGN) before or simultaneously to the time point the clinical sample was taken.</p></list-item></list>
</p><p id="Par23">Multivariable logistic regression analysis was performed to identify independent risk factors and confounders for the outcome &#x0201c;presence of PAE&#x0201d; in the positive clinical sample within 48&#x000a0;h after admission in the hospital. The multivariable model building strategy was performed in a stepwise backward approach. From a full model including all investigated parameters, non-significant parameters were removed with the significance level of <italic>p</italic>&#x02009;=&#x02009;0.05 and above.</p><p id="Par24">P-values less than 0.05 were considered significant. All analyses were exploratory in nature were performed using SPSS version 29 (IBM SPSS statistics, Somer, NY, USA) and SAS version 9.4 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par25">Of the 802,859 cases admitted to the hospital between 2015 and 2020 a total of 27,710 (3.45%) admitted cases had clinical samples with growth of GN-pathogens within 48&#x000a0;h from admission (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A total of 3764 (13.6%) patients had growth of PAE in a clinical sample. However, E. <italic>coli</italic> was the GN 14,142 (51%) most frequently detected followed by <italic>Klebsiella spp.</italic> 4432 (16%). Even though the frequency of GN-pathogens in clinical samples increased over time, their sequence did not (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par26">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients (<italic>N</italic>&#x02009;=&#x02009;27,710) with positive clinical sample with Gram negative-pathogen during the first 48&#x000a0;h from admission</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Total amount (%)/median (IQR)</th></tr></thead><tbody><tr><td align="left">Admissions</td><td align="left">27,710 (100%)</td></tr><tr><td align="left">Year 2015</td><td align="left">3413 (12.3%)</td></tr><tr><td align="left">Year 2016</td><td align="left">4172 (15.1%)</td></tr><tr><td align="left">Year 2017</td><td align="left">4170 (15%)</td></tr><tr><td align="left">Year 2018</td><td align="left">5111 (18.4%)</td></tr><tr><td align="left">Year 2019</td><td align="left">5542 (20%)</td></tr><tr><td align="left">Year 2020</td><td align="left">5302 (19.1%)</td></tr><tr><td align="left">Length of stay</td><td align="left">7 (4&#x02013;14)</td></tr><tr><td align="left">Age</td><td align="left">67 (53&#x02013;77)</td></tr><tr><td align="left">Gender female</td><td align="left">14,422 (52%)</td></tr><tr><td align="left">Gender male</td><td align="left">13,288 (48%)</td></tr><tr><td align="left">Comorbidities</td><td align="left"/></tr><tr><td align="left">Charlson Comorbidity Score</td><td align="left">5 (2&#x02013;8)</td></tr><tr><td align="left">Myocardial infarction</td><td align="left">558 (2%)</td></tr><tr><td align="left">Chronic heart failure</td><td align="left">3981 (14.4%)</td></tr><tr><td align="left">Peripheral vascular disease</td><td align="left">2111 (7.6%)</td></tr><tr><td align="left">Cerebrovascular disease</td><td align="left">2555 (9.2%)</td></tr><tr><td align="left">Dementia</td><td align="left">1438 (5.2%)</td></tr><tr><td align="left">Chronic pulmonary disease</td><td align="left">5573 (20.1%)</td></tr><tr><td align="left">Rheumatic disease</td><td align="left">1056 (3.8%)</td></tr><tr><td align="left">Peptic ulcer disease</td><td align="left">357 (1.3%)</td></tr><tr><td align="left">Mild liver disease</td><td align="left">1623 (5.9%)</td></tr><tr><td align="left">Diabetes without chronic complications</td><td align="left">4770 (17.2%)</td></tr><tr><td align="left">Diabetes with chronic complications</td><td align="left">1240 (4.5%)</td></tr><tr><td align="left">Chronic kidney disease</td><td align="left">10,333 (37.3%)</td></tr><tr><td align="left">Malignant tumor</td><td align="left">4911 (17.7%)</td></tr><tr><td align="left">Moderate to severe liver disease</td><td align="left">834 (3%)</td></tr><tr><td align="left">Metastasized solid tumor</td><td align="left">3032 (10.9%)</td></tr><tr><td align="left">AIDS HIV</td><td align="left">116 (0.4%)</td></tr><tr><td align="left">Hemiplegia</td><td align="left">2417 (8.7%)</td></tr><tr><td align="left">Leukaemia</td><td align="left">453 (1.6%)</td></tr><tr><td align="left">Lymphoma</td><td align="left">933 (3.4%)</td></tr><tr><td align="left">Type of Unit</td><td align="left"/></tr><tr><td align="left">Intensive care unit (ICU)</td><td align="left">4884 (17.6%)</td></tr><tr><td align="left">Regular ward (RW) &#x00026; intermediate care unit(IMC)</td><td align="left">22,826 (82.4%)</td></tr><tr><td align="left">Interdisciplinary</td><td align="left">4751 (17.1%)</td></tr><tr><td align="left">Neurology / Neurosurgery</td><td align="left">1606 (5.8%)</td></tr><tr><td align="left">Visceral surgery</td><td align="left">2600 (9.4%)</td></tr><tr><td align="left">Internal medicine</td><td align="left">5257 (19%)</td></tr><tr><td align="left">Nephrology</td><td align="left">3226 (11.6%)</td></tr><tr><td align="left">Pediatrics</td><td align="left">888 (3.2%)</td></tr><tr><td align="left">Oncology</td><td align="left">1908 (6.9%)</td></tr><tr><td align="left">Obstetrics &#x00026; Gynaecology</td><td align="left">1238 (4.5%)</td></tr><tr><td align="left">Urology</td><td align="left">1670 (6%)</td></tr><tr><td align="left">Cardiology / Visceral surgery</td><td align="left">2876 (10.4%)</td></tr><tr><td align="left">Cystic fibrosis</td><td align="left">994 (3.6%)</td></tr><tr><td align="left">Infectious Diseases</td><td align="left">1720 (6.2%)</td></tr><tr><td align="left">Anaesthesiology</td><td align="left">1481 (5.3%)</td></tr><tr><td align="left">other</td><td align="left">9366 (33.8%)</td></tr><tr><td align="left">Clinical Material</td><td align="left"/></tr><tr><td align="left">Blood culture</td><td align="left">3112 (11.2%)</td></tr><tr><td align="left">Gastrointestinal tract</td><td align="left">1246 (4.5%)</td></tr><tr><td align="left">CSF/otolaryngologic</td><td align="left">396 (1.4%)</td></tr><tr><td align="left">Respiratory Tract</td><td align="left">3255 (11.7%)</td></tr><tr><td align="left">Skeletal</td><td align="left">233 (0.8%)</td></tr><tr><td align="left">others</td><td align="left">5703 (20.6%)</td></tr><tr><td align="left">urine</td><td align="left">13,765 (49.7%)</td></tr><tr><td align="left">GN pathogen species</td><td align="left"/></tr><tr><td align="left">
<italic>Citrobacter spp.</italic>
</td><td align="left">811 (2.9%)</td></tr><tr><td align="left">
<italic>Enterobacter spp.</italic>
</td><td align="left">1769 (6.4%)</td></tr><tr><td align="left">
<italic>E. coli</italic>
</td><td align="left">14,142 (51%)</td></tr><tr><td align="left">
<italic>Klebsiella spp.</italic>
</td><td align="left">4432 (16%)</td></tr><tr><td align="left">
<italic>Morganella spp.</italic>
</td><td align="left">301 (1.1%)</td></tr><tr><td align="left">
<italic>P. aeruginosa</italic>
</td><td align="left">3764 (13.6%)</td></tr><tr><td align="left">
<italic>Proteus spp.</italic>
</td><td align="left">1919 (6.9%)</td></tr><tr><td align="left"><italic>Serratia spp</italic>.</td><td align="left">572 (2.1%)</td></tr><tr><td align="left">Infection &#x00026; MDR detection prior to invasive detection</td><td align="left"/></tr><tr><td align="left">Previous invasive <italic>P. aeruginosa</italic></td><td align="left">1071 (3.9%)</td></tr><tr><td align="left">Colonization MDR <italic>P. aeruginosa</italic></td><td align="left">630 (2.3%)</td></tr><tr><td align="left">Colonization MDR <italic>E. coli</italic></td><td align="left">1662 (6%)</td></tr><tr><td align="left">Colonization MDR <italic>Klebsiella spp.</italic></td><td align="left">599 (2.2%)</td></tr><tr><td align="left">Colonization MDR <italic>Enterobacter spp.</italic></td><td align="left">90 (0.3%)</td></tr><tr><td align="left">Colonization other MDRGN</td><td align="left">142 (0.5%)</td></tr></tbody></table></table-wrap>
</p><p id="Par27">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Yearly development of admitted cases with positive sample with GN-pathogens within the first 48&#x000a0;h from the admission to the hospital</p></caption><graphic xlink:href="13756_2025_1527_Fig1_HTML" id="d33e839"/></fig>
</p><p id="Par29">Patients with growth of GN-pathogens in clinical samples had a median age of 67 (IQR:53&#x02013;77). They had a median CCS of 5 (IQR:2&#x02013;8). The Univariable logistic regression identified several potential risk factors for the &#x0201c;presence of PAE&#x0201d; in clinical samples (Table <xref rid="Tab2" ref-type="table">2</xref>). Only for those deemed relevant and statitically significant multivariable analysis was performed.</p><p id="Par28">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Results of univariable analysis: admissions (<italic>N</italic>&#x02009;=&#x02009;27,710) with positive clinical sample with Gram negative-pathogen during the first 48&#x000a0;h from admission stratified by &#x0201c;presence of PAE&#x0201d; or not</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left"><italic>P</italic>. aeruginosa</th><th align="left"/><th align="left"/><th align="left"><italic>p</italic>-value</th></tr><tr><th align="left"/><th align="left">no</th><th align="left">yes</th><th align="left">% with <italic>P. aeruginosa</italic></th><th align="left"/></tr><tr><th align="left"/><th align="left">Total number (%)/median (IQR)</th><th align="left">Total number (%)/median (IQR)</th><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">Admissions</td><td align="left">23,946 (100%)</td><td align="left">3764 (100%)</td><td align="left">13.6%</td><td align="left"/></tr><tr><td align="left">Year 2015</td><td align="left">2974 (12.4%)</td><td align="left">439 (11.7%)</td><td align="left">12.9%</td><td char="." align="char">0.534</td></tr><tr><td align="left">Year 2016</td><td align="left">3603 (15%)</td><td align="left">569 (15.1%)</td><td align="left">13.6%</td><td align="left"/></tr><tr><td align="left">Year 2017</td><td align="left">3618 (15.1%)</td><td align="left">552 (14.7%)</td><td align="left">13.2%</td><td align="left"/></tr><tr><td align="left">Year 2018</td><td align="left">4382 (18.3%)</td><td align="left">729 (19.4%)</td><td align="left">14.3%</td><td align="left"/></tr><tr><td align="left">Year 2019</td><td align="left">4795 (20%)</td><td align="left">747 (19.8%)</td><td align="left">13.5%</td><td align="left"/></tr><tr><td align="left">Year 2020</td><td align="left">4574 (19.1%)</td><td align="left">728 (19.3%)</td><td align="left">13.7%</td><td align="left"/></tr><tr><td align="left">Length of Stay</td><td align="left">7 (4&#x02013;14)</td><td align="left">9 (5&#x02013;16)</td><td align="left"/><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Age</td><td align="left">68 (54&#x02013;77)</td><td align="left">64 (47&#x02013;76)</td><td align="left"/><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Gender male</td><td align="left">12,919 (54%)</td><td align="left">1503 (39.9%)</td><td align="left">10.4%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Gender female</td><td align="left">11,027 (46%)</td><td align="left">2261 (60.1%)</td><td align="left">17.0%</td><td align="left"/></tr><tr><td align="left">Comorbidities</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Charlson Comorbidity Score</td><td align="left">5 (2&#x02013;8)</td><td align="left">4 (2&#x02013;7)</td><td align="left"/><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Myocardial infarction</td><td align="left">517 (2.2%)</td><td align="left">41 (1.1%)</td><td align="left">7.3%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Chronic heart failure</td><td align="left">3579 (14.9%)</td><td align="left">402 (10.7%)</td><td align="left">10.1%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Peripheral vascular disease</td><td align="left">1906 (8%)</td><td align="left">205 (5.4%)</td><td align="left">9.7%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Cerebrovascular disease</td><td align="left">2145 (9%)</td><td align="left">410 (10.9%)</td><td align="left">16.0%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Dementia</td><td align="left">1315 (5.5%)</td><td align="left">123 (3.3%)</td><td align="left">8.6%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Chronic pulmonary disease</td><td align="left">3652 (15.3%)</td><td align="left">1921 (51%)</td><td align="left">34.5%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Rheumatic disease</td><td align="left">968 (4%)</td><td align="left">88 (2.3%)</td><td align="left">8.3%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Peptic ulcer disease</td><td align="left">311 (1.3%)</td><td align="left">46 (1.2%)</td><td align="left">12.9%</td><td char="." align="char">0.698</td></tr><tr><td align="left">Mild liver disease</td><td align="left">1274 (5.3%)</td><td align="left">349 (9.3%)</td><td align="left">21.5%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Diabetes without chronic complications</td><td align="left">4254 (17.8%)</td><td align="left">516 (13.7%)</td><td align="left">10.8%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Diabetes with chronic complications</td><td align="left">1131 (4.7%)</td><td align="left">109 (2.9%)</td><td align="left">8.8%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Chronic kidney disease</td><td align="left">9290 (38.8%)</td><td align="left">1043 (27.7%)</td><td align="left">10.1%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Malignant tumor</td><td align="left">4425 (18.5%)</td><td align="left">486 (12.9%)</td><td align="left">9.9%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Moderate to severe liver disease</td><td align="left">722 (3%)</td><td align="left">112 (3%)</td><td align="left">13.4%</td><td char="." align="char">0.895</td></tr><tr><td align="left">Metastasized solid tumor</td><td align="left">2767 (11.6%)</td><td align="left">265 (7%)</td><td align="left">8.7%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">AIDS HIV</td><td align="left">104 (0.4%)</td><td align="left">12 (0.3%)</td><td align="left">10.3%</td><td char="." align="char">0.308</td></tr><tr><td align="left">Hemiplegia</td><td align="left">1812 (7.6%)</td><td align="left">605 (16.1%)</td><td align="left">25.0%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Leukaemia</td><td align="left">389 (1.6%)</td><td align="left">64 (1.7%)</td><td align="left">14.1%</td><td char="." align="char">0.733</td></tr><tr><td align="left">Lymphoma</td><td align="left">863 (3.6%)</td><td align="left">70 (1.9%)</td><td align="left">7.5%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Type of Unit</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Intensive care unit (ICU)</td><td align="left">4064 (17%)</td><td align="left">820 (21.8%)</td><td align="left">16.8%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Regular ward (RW) &#x00026; intermediate care unit (IMC)</td><td align="left">19,882 (83%)</td><td align="left">2944 (78.2%)</td><td align="left">12.9%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Interdisciplinary</td><td align="left">4382 (18.3%)</td><td align="left">369 (9.8%)</td><td align="left">7.8%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Neurology / Neurosurgery</td><td align="left">1387 (5.8%)</td><td align="left">219 (5.8%)</td><td align="left">13.6%</td><td char="." align="char">0.949</td></tr><tr><td align="left">Visceral surgery</td><td align="left">2353 (9.8%)</td><td align="left">247 (6.6%)</td><td align="left">9.5%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Internal medicine</td><td align="left">4629 (19.3%)</td><td align="left">628 (16.7%)</td><td align="left">11.9%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Nephrology</td><td align="left">2901 (12.1%)</td><td align="left">325 (8.6%)</td><td align="left">10.1%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Paediatrics</td><td align="left">801 (3.3%)</td><td align="left">87 (2.3%)</td><td align="left">9.8%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Oncology</td><td align="left">1677 (7%)</td><td align="left">231 (6.1%)</td><td align="left">12.1%</td><td char="." align="char">0.051</td></tr><tr><td align="left">Obstetrics &#x00026; Gynaecology</td><td align="left">1187 (5%)</td><td align="left">51 (1.4%)</td><td align="left">4.1%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Urology</td><td align="left">1536 (6.4%)</td><td align="left">134 (3.6%)</td><td align="left">8.0%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Cardiology / Visceral surgery</td><td align="left">2645 (11%)</td><td align="left">231 (6.1%)</td><td align="left">8.0%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Cystic fibrosis</td><td align="left">90 (0.4%)</td><td align="left">904 (24%)</td><td align="left">90.9%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Infectious Diseases</td><td align="left">1483 (6.2%)</td><td align="left">237 (6.3%)</td><td align="left">13.8%</td><td char="." align="char">0.807</td></tr><tr><td align="left">Anaesthesiology</td><td align="left">1257 (5.2%)</td><td align="left">224 (6%)</td><td align="left">15.1%</td><td char="." align="char">0.075</td></tr><tr><td align="left">other</td><td align="left">8231 (34.4%)</td><td align="left">1135 (30.2%)</td><td align="left">12.1%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Type of clinical material</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Respiratory tract</td><td align="left">1839 (7.7%)</td><td align="left">1416 (37.6%)</td><td align="left">43.5%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Blood culture</td><td align="left">2936 (12.3%)</td><td align="left">176 (4.7%)</td><td align="left">5.7%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Urine</td><td align="left">12,855 (53.7%)</td><td align="left">910 (24.2%)</td><td align="left">6.6%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Skeletal</td><td align="left">216 (0.9%)</td><td align="left">17 (0.5%)</td><td align="left">7.3%</td><td char="." align="char">0.005</td></tr><tr><td align="left">Gastro intestinal tract</td><td align="left">1142 (4.8%)</td><td align="left">104 (2.8%)</td><td align="left">8.3%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Central nervous system; otorhinolaryngology</td><td align="left">358 (1.5%)</td><td align="left">38 (1%)</td><td align="left">9.6%</td><td align="left">0.020</td></tr><tr><td align="left">other</td><td align="left">4600 (19.2%)</td><td align="left">1103 (29.3%)</td><td align="left">19.3%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Infection &#x00026; MDRGN colonization</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Previous invasive <italic>P. aeruginosa</italic></td><td align="left">319 (1.3%)</td><td align="left">752 (20%)</td><td align="left">70.2%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Colonization MDR <italic>P. aeruginosa</italic></td><td align="left">51 (0.2%)</td><td align="left">579 (15.4%)</td><td align="left">91.9%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Colonization MDR <italic>E. coli</italic></td><td align="left">1541 (6.4%)</td><td align="left">121 (3.2%)</td><td align="left">7.3%</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Colonization MDR <italic>Klebsiella spp.</italic></td><td align="left">500 (2.1%)</td><td align="left">99 (2.6%)</td><td align="left">16.5%</td><td char="." align="char">0.033</td></tr><tr><td align="left">Colonization MDR <italic>Enterobacter spp.</italic></td><td align="left">81 (0.3%)</td><td align="left">9 (0.2%)</td><td align="left">10.0%</td><td char="." align="char">0.320</td></tr><tr><td align="left">Colonization other MDRGN</td><td align="left">110 (0.5%)</td><td align="left">32 (0.9%)</td><td align="left">22.5%</td><td char="." align="char">0.002</td></tr></tbody></table></table-wrap>
</p><p id="Par30">Multivariable logistic regression analysis identified a variety of independent risk factors for the outcome &#x0201c;presence of PAE&#x0201d; in clinical samples taken within the first 48&#x000a0;h from admission (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par31">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of multivariable logistic regression analysis for the outcome &#x0201c;presence <italic>of P. aeruginosa</italic>&#x0201d; in clinical sample with Gram negative-pathogen during the first 48&#x000a0;h from admission</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">OR</th><th align="left">95%CI</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">male</td><td align="left">1.599</td><td align="left">1.461&#x02013;1.75</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left" colspan="4">Comorbidities</td></tr><tr><td align="left">Myocardial infarction</td><td align="left">0.806</td><td align="left">0.706&#x02013;0.921</td><td align="left">0.0015</td></tr><tr><td align="left">Chronic heart failure</td><td align="left">0.803</td><td align="left">0.678&#x02013;0.952</td><td align="left">0.0114</td></tr><tr><td align="left">Chronic pulmonary disease</td><td align="left">2.045</td><td align="left">1.847&#x02013;2.263</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Mild liver disease</td><td align="left">0.686</td><td align="left">0.556&#x02013;0.847</td><td align="left">0.0005</td></tr><tr><td align="left">Diabetes with chronic complications</td><td align="left">0.716</td><td align="left">0.567&#x02013;0.903</td><td align="left">0.0048</td></tr><tr><td align="left">Chronic kidney disease</td><td align="left">0.905</td><td align="left">0.82&#x02013;0.997</td><td align="left">0.044</td></tr><tr><td align="left">Metastasized solid tumor</td><td align="left">0.847</td><td align="left">0.727&#x02013;0.988</td><td align="left">0.034</td></tr><tr><td align="left">Infection</td><td align="left">1.171</td><td align="left">1.049&#x02013;1.306</td><td align="left">0.0048</td></tr><tr><td align="left">Pneumonia</td><td align="left">1.349</td><td align="left">1.203&#x02013;1.513</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Hemiplegia</td><td align="left">2.157</td><td align="left">1.897&#x02013;2.453</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Leukaemia</td><td align="left">1.524</td><td align="left">1.117&#x02013;2.079</td><td align="left">0.0079</td></tr><tr><td align="left">Lymphoma</td><td align="left">0.715</td><td align="left">0.538&#x02013;0.95</td><td align="left">0.0208</td></tr><tr><td align="left" colspan="4">Type of ward</td></tr><tr><td align="left">Interdisciplinary</td><td align="left">0.742</td><td align="left">0.642&#x02013;0.856</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Neurology / Neurosurgery</td><td align="left">1.256</td><td align="left">1.049&#x02013;1.504</td><td align="left">0.0129</td></tr><tr><td align="left">Internal medicine</td><td align="left">1.347</td><td align="left">1.191&#x02013;1.523</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Oncology</td><td align="left">1.739</td><td align="left">1.446&#x02013;2.092</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Cardiology Visceral Surgery</td><td align="left">0.712</td><td align="left">0.598&#x02013;0.848</td><td align="left">0.0001</td></tr><tr><td align="left">Cystic fibrosis</td><td align="left">26.978</td><td align="left">20.481&#x02013;35.537</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">others</td><td align="left">1.401</td><td align="left">1.256&#x02013;1.564</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left" colspan="4">Type of clinical sample</td></tr><tr><td align="left">other</td><td align="left">1.338</td><td align="left">1.106&#x02013;1.618</td><td align="left">0.0027</td></tr><tr><td align="left">Respiratory tract</td><td align="left">1.534</td><td align="left">1.24&#x02013;1.898</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Blood culture</td><td align="left">0.419</td><td align="left">0.328&#x02013;0.534</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Urine</td><td align="left">0.525</td><td align="left">0.433&#x02013;0.638</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left" colspan="4">Infection &#x00026; MDRGN colonization</td></tr><tr><td align="left">Previous invasive <italic>P. aeruginosa</italic></td><td align="left">7.869</td><td align="left">6.601&#x02013;9.381</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Colonization MDR <italic>P. aeruginosa</italic></td><td align="left">39.401</td><td align="left">28.542&#x02013;54.391</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Colonization MDR <italic>E. coli</italic></td><td align="left">0.634</td><td align="left">0.471&#x02013;0.854</td><td align="left">0.0027</td></tr><tr><td align="left">Colonization MDR <italic>Klebsiella spp.</italic></td><td align="left">0.33</td><td align="left">0.256&#x02013;0.425</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Colonization MDR <italic>Enterobacter spp.</italic></td><td align="left">0.537</td><td align="left">0.301&#x02013;0.959</td><td align="left">0.0355</td></tr></tbody></table></table-wrap>
</p><p id="Par32">Male gender of patients increased the risk for presence of PAE OR 1.60 (95% CI 1.46&#x02013;1.75). Prior colonisation with a multi drug resistant PAE or detection of a PAE in clinical samples during a previous hospitalisation increased the risk OR 39.41 (95% CI 28.54&#x02013;54.39) and OR 7.869 (95% CI 6.60&#x02013;9.38) respectively.</p><p id="Par33">In addition, admission to a cystic fibrosis ward was associated with an increased risk of OR 26.99 (95% CI 20.48&#x02013;35.54). Admission to other types of wards such as oncology, internal medicine, neurology and others were only associated with a modest but statistically significant increased odds.</p><p id="Par34">Presence of chronic pulmonary disease OR 2.05 (95% CI 1.85&#x02013;2.26), hemiplegia OR 2.16 (95% CI1.90-2.45), leukaemia OR 1.52 (95% CI 1.12&#x02013;2.08), as well as the diagnosis of pneumonia OR 1.35 (95% CI 1.20&#x02013;1.51) and infection OR 1.17 (95% CI 1.05&#x02013;1.31) were associated with a modest increase in risk for presence of PAE.</p><p id="Par35">Growth of GN-pathogens in samples derived from the lower respiratory tract and other sites were associated with a modest increased risk for detection of PAE with OR 1.53 (95% CI 1.24&#x02013;1.90) and OR 1.34 (95% CI 1.11&#x02013;1.62) respectively.</p><p id="Par36">Interestingly enough the detection GN-pathogens in blood cultures and urine were associated with a statistically significant decreased risk for detection of PAE OR 0.42 (95% CI 0.33&#x02013;0.53) and OR 0.53 (95% CI 0.43&#x02013;0.67).</p><p id="Par37">In addition, we identified that patients that were colonized with MDRGN Enterobacterales prior to admission, had a decreased risk for invasive detection of PAE.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par38">In this retrospective single centre cohort study, we were able to identify novel as well as well-established risk factors for the presence of PAE in clinical samples acquired immediately after admission. Our findings could potentially support physicians in evaluation if antipseudomonal coverage in calculated antimicrobial therapy is necessary.</p><p id="Par39">Previous infection with PAE as well as colonisation are well known and internationally established risk factors for subsequent or re- infections with PAE [<xref ref-type="bibr" rid="CR22">22</xref>]. This is especially true for bacterial infections of the lower respiratory tract such as pneumonia [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par40">Patients with structural pulmonary disease have an increased risk for bacterial colonisation and infections with PAE [<xref ref-type="bibr" rid="CR22">22</xref>]. This is based as much on the medical condition itself, as on the recurrent medical treatment for infection and exacerbation often times with antibiotics [<xref ref-type="bibr" rid="CR23">23</xref>]. Similar observations are true for patients with hemiplegia. Those patients often spend prolonged durations of time in hospitals and rehabilitation facilities and potentially encounter repeated exposition to antibiotics as well as PAE.</p><p id="Par41">In patients with cystic fibrosis the course of disease is in direct correlation to the presence and infection with PAE in the lung [<xref ref-type="bibr" rid="CR24">24</xref>]. Cystic fibrosis is a known risk factor for PAE when compared to patients without. Due to this fact, studies investigating risk factors for PAE frequently exclude patients with cystic fibrosis in their analysis. However, we tried to achieve a full overview of risk factor for our setting. Only 994 adult patients (3.6%) of the cohort were admitted to the cystic fibrosis ward. Of whom 92 did not have PAE detected in their clinical samples.</p><p id="Par42">In general, PAE plays an important role in LRTI. The detection in microbiological samples derived from other sites is less common and potentially associated with underlying immunosuppressive medical conditions [<xref ref-type="bibr" rid="CR18">18</xref>]. Our data underline this fact with an increased independent risk for PAE if the sample is derived from the LRT and an independent risk reduction if samples such as blood cultures or even urine grew Gram-negative rods [<xref ref-type="bibr" rid="CR25">25</xref>]. So, in alternative sites of infection outside the respiratory tract, PAE is less likely to be the cause of infection [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par43">Colonization with MDRGN Enterobacterales was associated with significantly decreased risk for detection of PAE in clinical samples with Gram-negative rods upon admission. Underlying reasons could be based on differences ofcharacteristics in patients underlying conditions. Patients colonized with MDR <italic>E. coli</italic> are frequently less impaired and have a lower Charlson Comorbity Score compared to other Enterobacterales. Patients colonized with non-fermentative bacteria are known to even have more severe impairment and higher CharlsonComorbidity scores. In addition, prior antibiotic exposure, and differences in the susceptibility of pathogens could play an important role as well [<xref ref-type="bibr" rid="CR27">27</xref>]. CRE are relatively rare in Germany. However, nonspecific carbapenem resistance in PAE are the most frequently identified Carbapenem-resistant organisms [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par44">There are certain limitations that apply to this study. (i) The retrospective design of this study and the non-clinical definition for presence of PAE in clinical samples potentially affects our findings to a certain degree. Often patients that are colonized with MDRGN are believed to be similar to patients with predetected colonisation or infection with PAE However, in clinical medicine often the presence of a pathogen in a clinical sample is considered for the antibiotic treatment. (ii) Our findings might not be applicable for some other centers, since this cohort is derived from a single university hospital that consist of three independent hospitals and provides specialized care as including patient with cystic fibrosis as well as organ transplant. (iii) We were not able to differentiate between community acquired and healthcare associated infections with readmission. But often this not possible for the physicians evaluating the patients upon admission. iiii) Some of the variables used in this study rather represent surrogates than the directly measured information. iiiii) The definition used for MDRGN is specific to the German healthcare system and unfortunately cannot easily be extrapolated to international definitions.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par45"><italic>PAE</italic> is frequently cultured from clinical samples taken from patients within 48&#x000a0;h after admission. The overall most important risk factors are prior detection or cystic fibrosis. Knowledge of these risk factors upon admission can significantly help shaping the use of anti-pseudomonal antibiotics. Future studies should investigate the potential of such risk factor analysis in clinical routine for antibiotic prescriptions.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Funds of Charit&#x000e9;&#x02013;Universit&#x000e4;tsmedizin Berlin.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Author Contributions: Conceptualization, T.S.K. and R.R.; methodology, T.S.K., R.R. and R.L.; software, M.B., F.S., P.G. and R.L.; validation, T.S.K., F.S. and R.R.; formal analysis, T.S.K., F.S., S.S.,B.S. and R.R.; investigation, T.S.K., R.R. and R.L.; resources, P.G. and C.G.; data curation, R.R., F.S., T.S.K.; writing&#x02014;original draft preparation, T.S.K.,R.R. R.L. and P.G.; writing&#x02014;review and editing, T.S.K., R.R., F.S., D.G., M.B.,P.G. and R.L.; visualization, S.S. and F.S.; supervision, P.G., T.S.K., C.G.; project administration, T.S.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">The authors declare no competing interests.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par47">The authors declare no conflict of interest. Parts of this study were presented at ECCMID 2023 and DGHM annual meeting 2023 as part of a poster session.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><collab>Antimicrobial Resistance Collaborators</collab></person-group><article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title><source>Lancet Lond Engl 12 Februar</source><year>2022</year><volume>399</volume><issue>10325</issue><fpage>629</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl 12 Februar. 2022;399(10325):629&#x02013;55.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Cassini</surname><given-names>A</given-names></name><name><surname>H&#x000f6;gberg</surname><given-names>LD</given-names></name><name><surname>Plachouras</surname><given-names>D</given-names></name><name><surname>Quattrocchi</surname><given-names>A</given-names></name><name><surname>Hoxha</surname><given-names>A</given-names></name><name><surname>Simonsen</surname><given-names>GS</given-names></name></person-group><article-title>u. a. attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis</article-title><source>Lancet Infect Dis Januar</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30605-4</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cassini A, H&#x000f6;gberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS. u. a. attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis Januar. 2019;19(1):56&#x02013;66.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Remschmidt</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>E</given-names></name><name><surname>Schroeren-Boersch</surname><given-names>B</given-names></name><name><surname>Gastmeier</surname><given-names>P</given-names></name><name><surname>Schwab</surname><given-names>F</given-names></name></person-group><article-title>Surveillance of antibiotic use and resistance in Intensive Care Units (SARI)</article-title><source>Dtsch Arzteblatt Int 15 Dezember</source><year>2017</year><volume>114</volume><issue>50</issue><fpage>858</fpage><lpage>65</lpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Remschmidt C, Schneider S, Meyer E, Schroeren-Boersch B, Gastmeier P, Schwab F. Surveillance of antibiotic use and resistance in Intensive Care Units (SARI). Dtsch Arzteblatt Int 15 Dezember. 2017;114(50):858&#x02013;65.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>D</given-names></name><name><surname>Gladstone</surname><given-names>BP</given-names></name><name><surname>Burkert</surname><given-names>F</given-names></name><name><surname>Carrara</surname><given-names>E</given-names></name><name><surname>Foschi</surname><given-names>F</given-names></name><name><surname>D&#x000f6;bele</surname><given-names>S</given-names></name></person-group><article-title>u. a. effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis September</source><year>2017</year><volume>17</volume><issue>9</issue><fpage>990</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30325-0</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, D&#x000f6;bele S. u. a. effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis September. 2017;17(9):990&#x02013;1001.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kallen</surname><given-names>MC</given-names></name><name><surname>Binda</surname><given-names>F</given-names></name><name><surname>Ten Oever</surname><given-names>J</given-names></name><name><surname>Tebano</surname><given-names>G</given-names></name><name><surname>Pulcini</surname><given-names>C</given-names></name><name><surname>Murri</surname><given-names>R</given-names></name></person-group><article-title>u. a. comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: a cross-sectional survey</article-title><source>Int J Antimicrob Agents September</source><year>2019</year><volume>54</volume><issue>3</issue><fpage>338</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.06.005</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kallen MC, Binda F, Ten Oever J, Tebano G, Pulcini C, Murri R. u. a. comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: a cross-sectional survey. Int J Antimicrob Agents September. 2019;54(3):338&#x02013;45.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Oonsivilai</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Niehus</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name></person-group><article-title>Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: a modelling study and meta-analysis</article-title><source>PLoS Med Juni</source><year>2023</year><volume>20</volume><issue>6</issue><fpage>e1004013</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1004013</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Mo Y, Oonsivilai M, Lim C, Niehus R, Cooper BS. Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: a modelling study and meta-analysis. PLoS Med Juni. 2023;20(6):e1004013.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Plachouras D, K&#x000e4;rki T, Hansen S, Hopkins S, Lyytik&#x000e4;inen O, Moro ML. November, Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2018;23(46):1800393.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Aghdassi</surname><given-names>SJS</given-names></name><name><surname>Gastmeier</surname><given-names>P</given-names></name><name><surname>Piening</surname><given-names>BC</given-names></name><name><surname>Behnke</surname><given-names>M</given-names></name><name><surname>Pe&#x000f1;a Diaz</surname><given-names>LA</given-names></name><name><surname>Gropmann</surname><given-names>A</given-names></name></person-group><article-title>u. a. antimicrobial usage in German acute care hospitals: results of the third national point prevalence survey and comparison with previous national point prevalence surveys</article-title><source>J Antimicrob Chemother 1 April</source><year>2018</year><volume>73</volume><issue>4</issue><fpage>1077</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx494</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Aghdassi SJS, Gastmeier P, Piening BC, Behnke M, Pe&#x000f1;a Diaz LA, Gropmann A. u. a. antimicrobial usage in German acute care hospitals: results of the third national point prevalence survey and comparison with previous national point prevalence surveys. J Antimicrob Chemother 1 April. 2018;73(4):1077&#x02013;83.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Aghdassi SJS, Hansen S, Pe&#x000f1;a Diaz LA, Gropmann A, Saydan S, Geffers C. Healthcare-Associated infections and the Use of antibiotics in German hospitals&#x02014;results of the Point Prevalence Survey of 2022 and comparison with earlier findings. Dtsch Arzteblatt Int. 3. Mai 2024;(Forthcoming):arztebl.m2024.0033.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Adekoya</surname><given-names>I</given-names></name><name><surname>Maraj</surname><given-names>D</given-names></name><name><surname>Steiner</surname><given-names>L</given-names></name><name><surname>Yaphe</surname><given-names>H</given-names></name><name><surname>Moja</surname><given-names>L</given-names></name><name><surname>Magrini</surname><given-names>N</given-names></name></person-group><article-title>u. a. comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study</article-title><source>Lancet Infect Dis Oktober</source><year>2021</year><volume>21</volume><issue>10</issue><fpage>1429</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30854-9</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Adekoya I, Maraj D, Steiner L, Yaphe H, Moja L, Magrini N. u. a. comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. Lancet Infect Dis Oktober. 2021;21(10):1429&#x02013;40.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Munting</surname><given-names>A</given-names></name><name><surname>Regina</surname><given-names>J</given-names></name><name><surname>Damas</surname><given-names>J</given-names></name><name><surname>Lhopitallier</surname><given-names>L</given-names></name><name><surname>Kritikos</surname><given-names>A</given-names></name><name><surname>Guery</surname><given-names>B</given-names></name></person-group><article-title>u. a. impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital</article-title><source>Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis April</source><year>2022</year><volume>28</volume><issue>4</issue><fpage>558</fpage><lpage>63</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Munting A, Regina J, Damas J, Lhopitallier L, Kritikos A, Guery B. u. a. impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis April. 2022;28(4):558&#x02013;63.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>de With</surname><given-names>K</given-names></name><name><surname>Allerberger</surname><given-names>F</given-names></name><name><surname>Amann</surname><given-names>S</given-names></name><name><surname>Apfalter</surname><given-names>P</given-names></name><name><surname>Brodt</surname><given-names>HR</given-names></name><name><surname>Eckmanns</surname><given-names>T</given-names></name></person-group><article-title>u. a. strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious diseases</article-title><source>Infect Juni</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>395</fpage><lpage>439</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">de With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T. u. a. strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious diseases. Infect Juni. 2016;44(3):395&#x02013;439.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>A</given-names></name><name><surname>Richter</surname><given-names>SS</given-names></name><name><surname>Haessler</surname><given-names>S</given-names></name><name><surname>Lindenauer</surname><given-names>PK</given-names></name><name><surname>Yu</surname><given-names>PC</given-names></name><name><surname>Zilberberg</surname><given-names>MD</given-names></name></person-group><article-title>u. a. de-escalation of empiric antibiotics following negative cultures in hospitalized patients with pneumonia: Rates and outcomes</article-title><source>Clin Infect Dis off Publ Infect Dis Soc Am 26 April</source><year>2021</year><volume>72</volume><issue>8</issue><fpage>1314</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa212</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Deshpande A, Richter SS, Haessler S, Lindenauer PK, Yu PC, Zilberberg MD. u. a. de-escalation of empiric antibiotics following negative cultures in hospitalized patients with pneumonia: Rates and outcomes. Clin Infect Dis off Publ Infect Dis Soc Am 26 April. 2021;72(8):1314&#x02013;22.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Moehring</surname><given-names>RW</given-names></name><name><surname>Yarrington</surname><given-names>ME</given-names></name><name><surname>Warren</surname><given-names>BG</given-names></name><name><surname>Lokhnygina</surname><given-names>Y</given-names></name><name><surname>Atkinson</surname><given-names>E</given-names></name><name><surname>Bankston</surname><given-names>A</given-names></name></person-group><article-title>u. a. evaluation of an opt-out protocol for antibiotic de-escalation in patients with suspected Sepsis: a Multicenter, Randomized, Controlled Trial</article-title><source>Clin Infect Dis off Publ Infect Dis Soc Am 8 Februar</source><year>2023</year><volume>76</volume><issue>3</issue><fpage>433</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac787</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Moehring RW, Yarrington ME, Warren BG, Lokhnygina Y, Atkinson E, Bankston A. u. a. evaluation of an opt-out protocol for antibiotic de-escalation in patients with suspected Sepsis: a Multicenter, Randomized, Controlled Trial. Clin Infect Dis off Publ Infect Dis Soc Am 8 Februar. 2023;76(3):433&#x02013;42.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Waagsb&#x000f8;</surname><given-names>B</given-names></name><name><surname>Tranung</surname><given-names>M</given-names></name><name><surname>Dam&#x000e5;s</surname><given-names>JK</given-names></name><name><surname>Heggelund</surname><given-names>L</given-names></name></person-group><article-title>Antimicrobial therapy of community-acquired pneumonia during stewardship efforts and a coronavirus pandemic: an observational study</article-title><source>BMC Pulm Med 14 Oktober</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>379</fpage><pub-id pub-id-type="doi">10.1186/s12890-022-02178-6</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Waagsb&#x000f8; B, Tranung M, Dam&#x000e5;s JK, Heggelund L. Antimicrobial therapy of community-acquired pneumonia during stewardship efforts and a coronavirus pandemic: an observational study. BMC Pulm Med 14 Oktober. 2022;22(1):379.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Metlay</surname><given-names>JP</given-names></name><name><surname>Waterer</surname><given-names>GW</given-names></name><name><surname>Long</surname><given-names>AC</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Brozek</surname><given-names>J</given-names></name><name><surname>Crothers</surname><given-names>K</given-names></name></person-group><article-title>u. a. diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America</article-title><source>Am J Respir Crit Care Med 1 Oktober</source><year>2019</year><volume>200</volume><issue>7</issue><fpage>e45</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1164/rccm.201908-1581ST</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. u. a. diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 1 Oktober. 2019;200(7):e45&#x02013;67.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W et al. Dr&#x000f6;mann D, [Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (&#x000d6;GP), the Austrian Society for Infectious and Tropical Diseases (&#x000d6;GIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumol Stuttg Ger. September 2021;75(9):665&#x02013;729.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Royo-Cebrecos</surname><given-names>C</given-names></name><name><surname>Laporte-Amarg&#x000f3;s</surname><given-names>J</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>M</given-names></name><name><surname>Ruiz-Camps</surname><given-names>I</given-names></name><name><surname>Garcia-Vidal</surname><given-names>C</given-names></name><name><surname>Abdala</surname><given-names>E</given-names></name></person-group><article-title>u. a. Pseudomonas aeruginosa Bloodstream infections presenting with septic shock in Neutropenic Cancer patients: impact of empirical antibiotic therapy</article-title><source>Microorganisms 30 M&#x000e4;rz</source><year>2024</year><volume>12</volume><issue>4</issue><fpage>705</fpage><pub-id pub-id-type="doi">10.3390/microorganisms12040705</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Royo-Cebrecos C, Laporte-Amarg&#x000f3;s J, Pe&#x000f1;a M, Ruiz-Camps I, Garcia-Vidal C, Abdala E. u. a. Pseudomonas aeruginosa Bloodstream infections presenting with septic shock in Neutropenic Cancer patients: impact of empirical antibiotic therapy. Microorganisms 30 M&#x000e4;rz. 2024;12(4):705.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gudiol</surname><given-names>C</given-names></name><name><surname>Albasanz-Puig</surname><given-names>A</given-names></name><name><surname>Laporte-Amarg&#x000f3;s</surname><given-names>J</given-names></name><name><surname>Pallar&#x000e8;s</surname><given-names>N</given-names></name><name><surname>Mussetti</surname><given-names>A</given-names></name><name><surname>Ruiz-Camps</surname></name></person-group><article-title>I, u. a. clinical predictive model of Multidrug Resistance in Neutropenic Cancer patients with bloodstream infection due to Pseudomonas aeruginosa</article-title><source>Antimicrob Agents Chemother 24 M&#x000e4;rz</source><year>2020</year><volume>64</volume><issue>4</issue><fpage>e02494</fpage><lpage>19</lpage></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gudiol C, Albasanz-Puig A, Laporte-Amarg&#x000f3;s J, Pallar&#x000e8;s N, Mussetti A, Ruiz-Camps. I, u. a. clinical predictive model of Multidrug Resistance in Neutropenic Cancer patients with bloodstream infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 24 M&#x000e4;rz. 2020;64(4):e02494&#x02013;19.</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Seong</surname><given-names>H</given-names></name><name><surname>Noh</surname><given-names>JY</given-names></name><name><surname>Cheong</surname><given-names>HJ</given-names></name></person-group><article-title>u. a. risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: microbiological distribution, antibiotic resistance, and clinical outcomes</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>6</issue><fpage>e0270261</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0270261</pub-id><pub-id pub-id-type="pmid">35767562</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hyun H, Song JY, Yoon JG, Seong H, Noh JY, Cheong HJ. u. a. risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: microbiological distribution, antibiotic resistance, and clinical outcomes. PLoS ONE. 2022;17(6):e0270261.<pub-id pub-id-type="pmid">35767562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>A</given-names></name><name><surname>Palacios-Baena</surname><given-names>ZR</given-names></name><name><surname>L&#x000f3;pez-Cort&#x000e9;s</surname><given-names>LE</given-names></name><name><surname>Rodr&#x000ed;guez-Ba&#x000f1;o</surname><given-names>J</given-names></name></person-group><article-title>Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis</article-title><source>Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis August</source><year>2019</year><volume>25</volume><issue>8</issue><fpage>964</fpage><lpage>70</lpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rojas A, Palacios-Baena ZR, L&#x000f3;pez-Cort&#x000e9;s LE, Rodr&#x000ed;guez-Ba&#x000f1;o J. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis August. 2019;25(8):964&#x02013;70.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Restrepo</surname><given-names>MI</given-names></name><name><surname>Babu</surname><given-names>BL</given-names></name><name><surname>Reyes</surname><given-names>LF</given-names></name><name><surname>Chalmers</surname><given-names>JD</given-names></name><name><surname>Soni</surname><given-names>NJ</given-names></name><name><surname>Sibila</surname><given-names>O</given-names></name></person-group><article-title>u. a. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients</article-title><source>Eur Respir J August</source><year>2018</year><volume>52</volume><issue>2</issue><fpage>1701190</fpage><pub-id pub-id-type="doi">10.1183/13993003.01190-2017</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O. u. a. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J August. 2018;52(2):1701190.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujitani</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>VL</given-names></name><name><surname>Weingarten</surname><given-names>JA</given-names></name></person-group><article-title>Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source</article-title><source>Chest April</source><year>2011</year><volume>139</volume><issue>4</issue><fpage>909</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1378/chest.10-0166</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest April. 2011;139(4):909&#x02013;19.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>PJ</given-names></name><name><surname>Izydorcyzk</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>PW</given-names></name><name><surname>Yau</surname><given-names>Y</given-names></name></person-group><article-title>u. a. Pseudomonas aeruginosa strain-sharing in early infection among children with cystic fibrosis</article-title><source>Clin Infect Dis off Publ Infect Dis Soc Am 2 November</source><year>2021</year><volume>73</volume><issue>9</issue><fpage>e2521</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa788</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Stapleton PJ, Izydorcyzk C, Clark S, Blanchard A, Wang PW, Yau Y. u. a. Pseudomonas aeruginosa strain-sharing in early infection among children with cystic fibrosis. Clin Infect Dis off Publ Infect Dis Soc Am 2 November. 2021;73(9):e2521&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>S</given-names></name><name><surname>Bodro</surname><given-names>M</given-names></name><name><surname>Soriano</surname><given-names>A</given-names></name></person-group><article-title>Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections</article-title><source>Curr Opin Infect Dis 1 Dezember</source><year>2021</year><volume>34</volume><issue>6</issue><fpage>686</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000768</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Herrera S, Bodro M, Soriano A. Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections. Curr Opin Infect Dis 1 Dezember. 2021;34(6):686&#x02013;92.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Barat</surname><given-names>L</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>De Rosa</surname><given-names>F</given-names></name><name><surname>Gabarr&#x000fa;s</surname><given-names>A</given-names></name><name><surname>Esperatti</surname><given-names>M</given-names></name><name><surname>Terraneo</surname><given-names>S</given-names></name></person-group><article-title>u. a. intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance</article-title><source>J Infect Februar</source><year>2017</year><volume>74</volume><issue>2</issue><fpage>142</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2016.11.008</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Fern&#x000e1;ndez-Barat L, Ferrer M, De Rosa F, Gabarr&#x000fa;s A, Esperatti M, Terraneo S. u. a. intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J Infect Februar. 2017;74(2):142&#x02013;52.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Cobos-Trigueros</surname><given-names>N</given-names></name><name><surname>Sol&#x000e9;</surname><given-names>M</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>C</given-names></name><name><surname>Rinaudo</surname><given-names>M</given-names></name></person-group><article-title>u. a. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure</article-title><source>Crit Care Lond Engl 4 Mai</source><year>2015</year><volume>19</volume><issue>1</issue><fpage>218</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-0916-7</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Cobos-Trigueros N, Sol&#x000e9; M, Castro P, Torres JL, Hern&#x000e1;ndez C, Rinaudo M. u. a. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care Lond Engl 4 Mai. 2015;19(1):218.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kresken</surname><given-names>M</given-names></name><name><surname>Wohlfarth</surname><given-names>E</given-names></name><name><surname>Wichelhaus</surname><given-names>TA</given-names></name><name><surname>Gatermann</surname><given-names>SG</given-names></name><name><surname>Pfennigwerth</surname><given-names>N</given-names></name><name><surname>Eisfeld</surname><given-names>J</given-names></name></person-group><article-title>u. a. susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam</article-title><source>Microb Drug Resist Larchmt N April</source><year>2023</year><volume>29</volume><issue>4</issue><fpage>138</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1089/mdr.2022.0175</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J. u. a. susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam. Microb Drug Resist Larchmt N April. 2023;29(4):138&#x02013;44.</mixed-citation></citation-alternatives></ref></ref-list></back></article>